Jim Simons Chemo Centryx, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 13, 2021	SELL	$49.53 - $68.4 $3.27 Million - $4.52 Million	-66,100 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$47.25 - $65.16 $3.12 Million - $4.31 Million	66,100 New	66,100 $4.09 Million
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $12.3 Million - $16.4 Million	-265,100 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$38.58 - $65.07 $2.25 Million - $3.79 Million	-58,200 Reduced 18.0%	265,100 $15.3 Million
Q1 2020 May 14, 2020	SELL	$32.73 - $50.78 $14.6 Million - $22.6 Million	-445,281 Reduced 57.94%	323,300 $13 Million

Q4 2019 Feb 13, 2020	SELL	$6.81 - $39.55 $3.59 Million - $20.9 Million	-527,398 Reduced 40.69%	768,581 $30.4 Million
Q3 2019 Nov 13, 2019	SELL	$6.47 - $8.96 $1.1 Million - $1.52 Million	-169,402 Reduced 11.56%	1,295,979 $8.79 Million
Q2 2019 Aug 12, 2019	BUY	$8.31 - $14.85 $2.76 Million - $4.93 Million	332,127 Added 29.31%	1,465,381 $13.6 Million
Q1 2019 May 14, 2019	BUY	$10.01 - $13.89 $2.5 Million - $3.47 Million	249,873 Added 28.29%	1,133,254 $15.7 Million
Q4 2018 Feb 13, 2019	BUY	$9.15 - $12.26 $8.08 Million - $10.8 Million	883,381 New	883,381 $9.64 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.